EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Carrimycin suppresses the TCF3-BCR signaling axis and induces oxidative DNA damage in Burkitt lymphoma

Qingfeng Xue, Juan Ye, Herui Wang, Han Ye, Yaping Zhang, Shuran Chen, Zhengping Zhuang

Apoptosis · 2026-12 · 31 (12)

DOI: 10.1007/s10495-026-02477-x ↗
AbstractBibliografische Angaben

Abstract

Abstract Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy with poor outcomes in relapsed or central nervous system (CNS)-involved cases. This study investigates the antitumor mechanism of Carrimycin, a genetically engineered macrolide antibiotic, in BL. In vitro assays demonstrated that Carrimycin exerts potent, dose-dependent cytotoxicity, inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis. Mechanistically, it triggered the generation of reactive oxygen species (ROS), leading to DNA damage. Transcriptomic profiling and molecular assays revealed that Carrimycin binds to the transcription factor 3 (TCF3), causing a collapse of the tonic B-cell receptor (BCR) signaling pathway. Genetic knockdown of TCF3 partially rescued BL cells from Carrimycin-induced cytotoxicity, confirming this molecular dependency. In vivo, Carrimycin suppressed tumor burden and prolonged survival in both subcutaneous and intracranial models with a favorable safety profile. In conclusion, Carrimycin is a therapeutic agent that targets TCF3 to inhibit the tonic BCR signaling axis while simultaneously driving lethal oxidative stress. Its systemic and intracranial efficacy positions Carrimycin as a highly promising candidate for clinical translation in high-risk and CNS-involved BL.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →